Pietsch EC, Humbey O and ME Murphy. Polymorphisms in the p53 pathway. Oncogene 25: 1602-1611, 2006.
Tang B, Kadariya Y, Murphy ME, Kruger WD. The methionine salvage pathway compound 4-methylthio-2-oxobutanate causes apoptosis independent of down-regulation of ornithine decarboxylase. Biochem Pharmacol. 72:806-15, 2006.
Murphy ME. Polymorphic variants in the p53 pathway. Cell Death Differ. 13:916-20, 2006.
Lin T, Chao C, Shin’ichi S, Murphy ME, Appella E and Xu Y. p53 regulates the differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nature Cell Biology 7:165-71, 2005.
Li X, Dumont P, Della Pietra AC, Shetler C and Murphy ME. The codon 47 polymorphism in p53 is functionally significant. J Biol Chem, 280:24245-51, 2005.
Leu JI., Dumont P, Hafey M., Murphy ME, George DL. Mitochondrial p53 activates BAK and leads to disruption of a BAK/MCL1 complex. Nature Cell Biology, 6:443-50, 2004.
Abdul Razak ZR, Varkonyi RJ, Kulp-McEliece M, Caslini C, Testa JR, Murphy ME,and Broccoli D. p53 differentially inhibits cell growth depending upon the mechanism of telomere maintenance. Mol Cell Biol, 24:5967-77, 2004.
Murphy ME, Leu JI, George DL. p53 moves to mitochondria: a turn on the path to apoptosis. Cell Cycle 3:836-9, 2004.
Biade, S., Murphy, M.E. Differential display techniques to identify tumor suppressor gene pathways. Methods Mol. Biol. 222:481-490, 2003.
Dumont P., Leu JI, Della Pietra AC, George DL, and Murphy ME. The codon 72 polymorphic variants of p53 demonstrate markedly different apoptotic potential. Nature Genetics 33:357-365, 2003.
Dumont, P., Della Pietra, A., Murphy, M.E. Methods to study p53-repressed promoters. Methods Mol. Biol. 234:111-120, 2003.
Murphy, M.E. The thousand doors that lead to death: p53-dependent repression and apoptosis. Cancer Biol. Ther. 2:381-382, 2003.
Sax, J.K., Stoddard, A., Murphy, M.E., Chodosh, L., El-Deiry, W.S. Microarray expression profiling of p53-dependent transcriptional changes in an immortalized mouse embryo fibroblast cell line. Cancer Biol. Ther. 2:416-430, 2003.
Bao, R., Connolly, D.C., Murphy, M., Green, J., Weinstein, J.K., Pisarcik, D.A., Hamilton, T.C. Use of the survivin promoter to activate cancer-specific gene expression. J. Natl. Cancer Inst. 94:522-528, 2002.
Hoffman, W.H., Biade, S., Zilfou, J.T., Chen, J., Murphy, M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem. 277:3247-3257, 2002.
Ma, J., Murphy, M., O'Dwyer, P., Berman, P., Reed, K., Gallo, J.M. Multi-drug resistant phenotype of a temozolomide (TMZ)-acquired resistant human glioma cell line. Biochem. Pharmacol. 63:1219-1228, 2002.
Sax, J.K., Fei, P., Murphy, M., Bernhard, E., Korsmeyer, S.J., El-Deiry, W.S. BID transcriptional regulation by p53 contributes to chemosensitivity. Nat. Cell. Biol. 4:842-849, 2002.
Koumenis, C., Alarcon, R., Hammond, E., Sutphin, P., Hoffman, W., Murphy, M., Derr, J., Taya, Y., Kastan, M., Giaccia, A. Regulation of p53 by hypoxia: Dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol. Cell Biol. 21:1297-1310, 2001.
Murphy, M. The battle between tumor suppressors: Is gene therapy using p16INK4a more efficacious than p53 for treatment of ovarian carcinoma? Clin. Cancer Res. 7:1487-1489, 2001.
Shen, H., Chen, Z.J., Zilfou, J.T., Hopper, E., Murphy, M., Tew, K.D. Binding of the aminothiol WR-1065 to transcription factors influences the cellular response to anticancer drugs. J. Pharmacol. Exp. Ther. 297:1067-1073, 2001.
Zilfou, J., Hoffman, W.H., Sank, M., George, D.L., Murphy, M. The co-repressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation. Mol. Cell Biol. 21:3974-3985, 2001.